Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the development of Olumiant) at the annual European Academy of Dermatology and Venereology Congress (EADV) in Geneva, Switzerland.
Lilly will also present data for Taltz® (ixekizumab) from 11 abstracts, including six oral presentations in psoriasis.
Highlighted abstracts include one late-breaker presentation showcasing Phase 3 data evaluating Taltz for the treatment of moderate-to-severe genital psoriasis, as well as long-term results from a five-year, open-label study in moderate-to-severe plaque psoriasis.
Analyses from the IXORA-S study comparing Taltz to Stelara®* (ustekinumab) and integrated safety and efficacy results from the SPIRIT-P1 and SPIRIT-P2 studies evaluating Taltz for the treatment of active psoriatic arthritis will also be presented.
Two e-posters from the Closer Together Survey, a survey where 1,457 people with moderate-to-severe psoriasis from 10 countries across Europe and Canada shared how psoriasis impacts their quality of life and their overall satisfaction with treatment, will also be presented. An additional four abstracts will detail results from a selection of studies evaluating the impact of immune-mediated diseases.